Ro vs Direct Meds
Two GLP-1 desks, one scoreboard. We put Ro and Direct Meds head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.
The verdict
Ro takes this head-to-head.
Ro scores 87 to 82 on our six-factor Brief Score — A heavyweight platform with brand-name access and a polished experience — but it keeps compounded pricing off the record.
That doesn't make Direct Meds a bad call — it's best for readers who want a needle-free oral or sublingual route on either molecule and an all-inclusive price with no separate membership — and who are comfortable that the figures are company-stated rather than checkout-verified. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Ro | Direct Meds | |
|---|---|---|
| Brief Score | 87/100 (B+) | 82/100 (B−) |
| Semaglutide | Not disclosed | $179/mo |
| Tirzepatide | Not disclosed | $224/mo |
| Coverage | Multi-state | Not publicly listed |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Yes |
| On the tracker | Stableprice stable | Stableprice stable |
Ro: Brand-name access and insurance navigation, but compounded pricing stays off the record.
Direct Meds: Company-stated rates unchanged this cycle — but we price these off the desk's own listings, not a live-verified checkout, so treat them as indicative.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.